The misfolded pro-inflammatory protein S100A9 disrupts memory via neurochemical remodelling instigating an Alzheimer’s disease-like cognitive deficit
暂无分享,去创建一个
R. Sewell | Ludmilla A. Morozova-Roche | Marina A. Gruden | Tatiana V. Davydova | Chao Wang | Victor B. Narkevich | Valentina G. Fomina | Vladimir S. Kudrin | Robert D.E. Sewell | M. Gruden | L. Morozova-Roche | V. Kudrin | V. Narkevich | Chao Wang | T. V. Davydova | V. G. Fomina
[1] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[2] W. Bowers,et al. Tumor Necrosis Factor-α Potentiates Intraneuronal Ca2+ Signaling via Regulation of the Inositol 1,4,5-Trisphosphate Receptor* , 2008, Journal of Biological Chemistry.
[3] K. Yanamandra,et al. Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine , 2013, Behavioural Brain Research.
[4] T. Vogl,et al. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. , 2003, Trends in immunology.
[5] Keith A. Johnson,et al. Functional Alterations in Memory Networks in Early Alzheimer’s Disease , 2010, NeuroMolecular Medicine.
[6] M. Hüll,et al. Microglial activation in Alzheimer's disease. , 2009, Current Alzheimer research.
[7] J. Ruysschaert,et al. Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. , 2015, The Biochemical journal.
[8] Carl W. Cotman,et al. In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.
[9] J. D. McGaugh,et al. Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease. , 2012, Learning & memory.
[10] Y. Suh,et al. S100a9 Knockdown Decreases the Memory Impairment and the Neuropathology in Tg2576 Mice, AD Animal Model , 2010, PloS one.
[11] S. Salamat,et al. Oncogenic Kras Expression in Postmitotic Neurons Leads to S100A8-S100A9 Protein Overexpression and Gliosis* , 2012, The Journal of Biological Chemistry.
[12] W. Nacken,et al. S100A9 Knockout Decreases the Memory Impairment and Neuropathology in Crossbreed Mice of Tg2576 and S100A9 Knockout Mice Model , 2014, PloS one.
[13] Robert Lalonde,et al. Relations between open-field, elevated plus-maze, and emergence tests as displayed by C57/BL6J and BALB/c mice , 2008, Journal of Neuroscience Methods.
[14] M. Zarrindast,et al. Influence of morphine on medial prefrontal cortex alpha2 adrenergic system in passive avoidance learning in rats , 2015, Pharmacology Biochemistry and Behavior.
[15] C. Belzung,et al. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. , 2003, European journal of pharmacology.
[16] K. Wada,et al. Stress-induced impairment of inhibitory avoidance learning in female neuromedin B receptor-deficient mice , 2003, Physiology & Behavior.
[17] S. Shankar,et al. The role of pro-inflammatory S100A9 in Alzheimer’s disease amyloid-neuroinflammatory cascade , 2013, Acta Neuropathologica.
[18] Elizabeth Head,et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers , 2007, Molecular Neurodegeneration.
[19] R. Sewell,et al. Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with α-synuclein aggregates which incite parkinsonian-like symptoms , 2015, Behavioural Brain Research.
[20] L. Lue,et al. Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .
[21] R. Donato,et al. Functions of S100 proteins. , 2012, Current molecular medicine.
[22] P. Hof,et al. Does Alzheimer's disease begin in the brainstem? , 2009, Neuropathology and applied neurobiology.
[23] K. Rayevsky,et al. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice , 2011, Neuroscience.
[24] B. Austen,et al. Amyloid-β Acts as a Regulator of Neurotransmitter Release Disrupting the Interaction between Synaptophysin and VAMP2 , 2012, PloS one.
[25] R. Veerhuis,et al. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology , 2006, International Journal of Developmental Neuroscience.
[26] R. Sewell,et al. Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Aβ(25–35) oligomers, S100b and neurotransmitters , 2007, Journal of Neuroimmunology.
[27] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[28] J. Segura-Aguilar,et al. Protective and toxic roles of dopamine in Parkinson's disease , 2014, Journal of neurochemistry.
[29] C. Dobson,et al. Antibodies and protein misfolding: From structural research tools to therapeutic strategies. , 2014, Biochimica et biophysica acta.
[30] D. Zimmer,et al. The Ca2+ sensor S100A1 modulates neuroinflammation, histopathology and Akt activity in the PSAPP Alzheimer's disease mouse model. , 2014, Cell calcium.
[31] S. Phipps,et al. RAGE and TLRs: relatives, friends or neighbours? , 2013, Molecular immunology.
[32] Norbert Sachser,et al. Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer’s disease , 2009, Neurobiology of Aging.
[33] E. Mufson,et al. Nigrostriatal Dysfunction in Familial Alzheimer's Disease-Linked APPswe/PS1ΔE9 Transgenic Mice , 2005, The Journal of Neuroscience.
[34] L. Lue,et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.
[35] Hugo M. Botelho,et al. Natural and amyloid self‐assembly of S100 proteins: structural basis of functional diversity , 2010, The FEBS journal.
[36] C. Masters,et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.
[37] O. Mutlu,et al. Effects of 7-NI and ODQ on memory in the passive avoidance, novel object recognition, and social transmission of food preference tests in mice , 2014, Medical science monitor basic research.
[38] George Perry,et al. Transgenic Mouse Models of Alzheimer’s Disease: Behavioral Testing and Considerations , 2009 .
[39] N. Pivac,et al. Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review. , 2015, Psychiatria Danubina.
[40] L. Nyberg,et al. Linking cognitive aging to alterations in dopamine neurotransmitter functioning: Recent data and future avenues , 2010, Neuroscience & Biobehavioral Reviews.
[41] O. Garaschuk,et al. Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.
[42] J. Seamans,et al. Selective Roles for Hippocampal, Prefrontal Cortical, and Ventral Striatal Circuits in Radial-Arm Maze Tasks With or Without a Delay , 1997, The Journal of Neuroscience.
[43] Martin Sarter,et al. Modeling falls in Parkinson's disease: Slow gait, freezing episodes and falls in rats with extensive striatal dopamine loss , 2015, Behavioural Brain Research.
[44] Joseph P Huston,et al. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease , 2001, Behavioural Brain Research.
[45] H. Levine,et al. Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.
[46] L. Lue,et al. Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease , 2001, Neurochemistry International.
[47] L. Chew,et al. S100A9 induces aggregation-prone conformation in Abeta peptides: a combined experimental and simulation study , 2013 .
[48] G. Miller,et al. Detection of Behavioral Impairments Correlated to Neurochemical Deficits in Mice Treated with Moderate Doses of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , 2002, Experimental Neurology.
[49] J. Gilthorpe,et al. MRP14 (S100A9) Protein Interacts with Alzheimer Beta-Amyloid Peptide and Induces Its Fibrillization , 2012, PloS one.
[50] O. Forlenza,et al. Alzheimer's disease. , 2012, Sub-cellular biochemistry.
[51] G. Arendash,et al. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease , 2009, Glia.
[52] E. Masliah,et al. Molecular mechanisms of neurodegeneration in Alzheimer's disease. , 2010, Human molecular genetics.
[53] Y. Suh,et al. The Role of S100a9 in the Pathogenesis of Alzheimer’s Disease: The Therapeutic Effects of S100a9 Knockdown or Knockout , 2012, Neurodegenerative Diseases.
[54] Teruhiko Yoshida,et al. Proinflammatory Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE , 2015, The Journal of Immunology.
[55] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[56] S. Tonegawa,et al. Differentiation of forebrain and hippocampal dopamine 1‐class receptors, D1R and D5R, in spatial learning and memory , 2015, Hippocampus.
[57] M. Tiwari,et al. β-Amyloid pathogenesis: Chemical properties versus cellular levels , 2016, Alzheimer's & Dementia.
[58] L. Colgin. Oscillations and hippocampal–prefrontal synchrony , 2011, Current Opinion in Neurobiology.
[59] C. Barrow,et al. Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases. , 2002, Current medicinal chemistry.
[60] C. Dobson,et al. The amyloid state and its association with protein misfolding diseases , 2014, Nature Reviews Molecular Cell Biology.
[61] C. Cotman,et al. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. , 1991, Brain research.
[62] Bill Y. Lin,et al. Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care , 2013, Neuroscience & Biobehavioral Reviews.
[63] T. Vogl,et al. Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. , 2006, Biochimica et biophysica acta.
[64] G. Barker,et al. When Is the Hippocampus Involved in Recognition Memory? , 2011, The Journal of Neuroscience.
[65] P. Rouleau,et al. Proinflammatory Activities of S100: Proteins S100A8, S100A9, and S100A8/A9 Induce Neutrophil Chemotaxis and Adhesion 1 , 2003, The Journal of Immunology.
[66] G. Cole,et al. Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. , 2010, CNS & neurological disorders drug targets.
[67] M. Benson,et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis , 2012, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[68] Sofia B. Carvalho,et al. Intrinsically Disordered and Aggregation Prone Regions Underlie β-Aggregation in S100 Proteins , 2013, PloS one.
[69] Marco Bozzali,et al. Dopaminergic Modulation of Cortical Plasticity in Alzheimer’s Disease Patients , 2014, Neuropsychopharmacology.
[70] R. Sewell,et al. Autoimmune Responses to Amyloid Structures of Aβ(25–35) Peptide and Human Lysozyme in the Serum of Patients with Progressive Alzheimer’s Disease , 2004, Dementia and Geriatric Cognitive Disorders.
[71] G. Halliday,et al. Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease , 2006, Neurobiology of Aging.
[72] T. Vogl,et al. Pro-Inflammatory S100A8 and S100A9 Proteins: Self-Assembly into Multifunctional Native and Amyloid Complexes , 2012, International journal of molecular sciences.
[73] J. Becker,et al. Extrapyramidal signs in patients with probable Alzheimer disease. , 1997, Archives of neurology.
[74] F. Kametani. S100A9/Mrp14 Plays an Important Role in Ab Amyloidosis Enhancement , 2014 .
[75] G. Koch,et al. “Is dopamine involved in Alzheimer's disease?” , 2014, Front. Aging Neurosci..
[76] M. Agaibyi. S100 Protein Family and its Application in Clinical Practice , 2016 .
[77] P. Mcgeer,et al. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. , 2010, Journal of Alzheimer's disease : JAD.
[78] C. Dobson,et al. Bridging the gap: From protein misfolding to protein misfolding diseases , 2009, FEBS letters.
[79] Vivian V. Valentin,et al. Differential effects of dopamine-directed treatments on cognition , 2015, Neuropsychiatric disease and treatment.